A study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral ubrogepant in the acute treatment of migraine in pediatric subjects.
Criteria:Aged 6 to 17.
History of migranes with or without aura for at least 6 months.
Have typical untreated migraine attacks lasting 3 or more hours, and '
Experience 1 to 14 migraine attacks with moderate to severe headaches per month by history in each of the 2 months prior to screening.